StockTipsArenaBeta

BUY Lupin Limited — Ajit Mishra, Religare

BUYLupin Limited

byAjit Mishra, ReligareHorizon: NA (inferred 1–3 months)6 Apr 2026via NDTV Profit

Entry₹2,400Inferred
Target₹2,700
Total upside +12.50% (call closed)
Stop loss₹2,100-12.50% risk
At expiry₹2,491.66 Jul 2026, 3:30 pm
Expired+3.82%
Follow Ajit Mishra for new calls(44% target hit, 18 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 1 active Short-term call on LUPINSee 16 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 6 Jul 2026
21 supporting1 neutral0 opposing
Supports the BUY call (21)

Lupin Limited has been recognized among the World's Most Sustainable Companies by TIME and Statista.

NSE · Press Release·6 Jul · today

(opens in new tab)

4 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·3 Jul · 2d ago

Lupin Ltd has received an Establishment Inspection Report (EIR) from the U.S. FDA for its Somerset facility, classifying it with Voluntary Action Indicated (VAI).

BSE · Company Update·1 Jul · 4d ago

(opens in new tab)

Lupin Ltd provided updates on the acquisition of minority shareholding in its subsidiary, Multicare Pharmaceuticals Philippines, Inc. (MPPI), and a share buyback by MPPI.

BSE · Company Update·1 Jul · 4d ago

(opens in new tab)

Lupin announced that the European Medicines Agency (EMA) has approved a change to the marketing authorization for NaMuscla, including new dosage strengths and expanded pediatric indications for non-dy

BSE · Company Update·1 Jul · 4d ago

(opens in new tab)
Neutral / worth noting (1)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.